CompletedNCT01196676
Single-Dose Safety and Drug Levels of AZD4451
About this title
Read the official source — NCT01196676Medication studyAges 18–55United StatesBipolarity
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 63
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01196676
- Official title
Show the full official title
A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single-center Study, to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 Following Single Ascending Oral Dose Administration in Healthy Subjects
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Overland Park
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including AZD4451 and Placebo.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
